- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 23, 2013 | 03:43 PM EDT
We view this announcement of the replacement for its retiring executive as a positive and we remain bullish on the shares. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 22, 2013 | 10:27 AM EDT
The stock has doubled over the past three months and we don't want to be greedy with our gains. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 23, 2013 | 01:40 PM EDT
Expectations demand that the company meet consensus estimates and at least maintain its guidance. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Endo Health Solutions Inc (ENDP)
ENDP (NASDAQ:Drugs)
$34.28
+0.66
+1.96%
Today's Range: 33.39 - 34.36 |
ENDP Avg Daily Volume: 2,637,500
| Last Update: 05/23/13 - 4:00 PM EDT |
| Volume: 1,069,064 |
| YTD Performance: 28.17% |
| Open: $33.73 |
| Previous Close: $33.62 |
| 52 Week Range: $25.01 - $38.32 |
| Oustanding Shares: 112,240,884 |
| Market Cap: 3,773,538,520 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 7 | 7 | 5 | 9 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 4 | 3 | 3 | 2 |
| Mean Rec. | 2.67 | 2.44 | 2.38 | 2.37 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $1.17 | $1.07 | $4.31 | $3.63 |
| Number of Analysts | 12 | 11 | 14 | 13 |
| High Estimate | $1.23 | $1.21 | $4.70 | $4.29 |
| Low Estimate | $1.11 | $0.96 | $4.00 | $2.81 |
| Prior Year | $1.27 | $1.28 | $5.02 | $4.31 |
| Growth Rate (Year over Year) | -8.20% | -16.05% | -14.06% | -15.79% |
BV_Healthcare: $ENDP Endo Health Solutions Inc Files 8-K : Submission of Matters to a Vote of Sec.. http://t.co/dFGb4ZfxYq
15 hours ago from BoardVote.com
15 hours ago from BoardVote.com
coryrenauer: #FDA #OxyContin #Painkiller Abuse Concerns Creating Opportunity For #Pfizer http://t.co/KHDr4fwLx3 $ACT $ENDP $PTIE $DRRX $PFE
3 days ago from Tweet Button
3 days ago from Tweet Button
JohnnyTrades1: Commented on StockTwits: Here are his top holdings $EQT $AMZN $SU $V $CHK $AET $ENDP SAC Capital http://t.co/Tc7rU2EXKc
4 days ago from StockTwits Web
4 days ago from StockTwits Web
SeekingAlpha: FDA Painkiller Abuse Concerns Creating Opportunity For Pfizer http://t.co/nEZltxBjlu $ACT $ENDP $PTIE $DRRX $PFE
4 days ago from Seeking Alpha
4 days ago from Seeking Alpha
tradingview: $ENDP chart by StockFan26: http://t.co/lFHg4uWsaV ENDP long setup.
4 days ago from TradingView
4 days ago from TradingView
micenter: Endo Pharmaceuticals $ENDP Showing Bullish Technicals With Resistance At $35.41 ( http://t.co/oBn2QsonOg )
4 days ago from Marketintelligencecenter.com
4 days ago from Marketintelligencecenter.com
JPZaragoza1: RT @TroKalayjianCRG "@JPZaragoza1 $depo $drrx $ptie $endp $acur " // other failed reformulated drugs, thx Tro!
4 days ago from web
4 days ago from web
BioWireFeed: Some Bear Sentiment Names, High Put/Call Volume: Endo $ENDP (27) Ironwood $IRWD (25) Synta $SNTA (10) Derma $DSCI (10) BioMarin $BMRN (6)
7 days ago from web
7 days ago from web
jkreiling3: @jimcramer how do you feel about $ENDP recovery from Monday's drop?
7 days ago from Twitter for Android
7 days ago from Twitter for Android
Endo price target and estimates reduced at UBS
ENDP estimates were reduced after the FDA denied Opana CP, said UBS. Price target goes to $39.
Endo Health downgraded at Lazard
ENDP was downgraded from Neutral to Sell, Lazard Capital Markets said. $27 price target. FDA denied Opana CP.
Endo Pharmaceuticals downgraded at Piper
ENDP was downgraded from Neutral to Underweight, Piper Jaffray said. $22 price target. Outlook for generic competition remains uncertain.
Endo Health Solutions downgraded at Oppenheimer
Shares of ENDP downgraded to Perform from Outperform, Oppenheimer said. Valuation call.
Endo Health Solutions numbers lowered at UBS
Shares of ENDP now seen reaching $40, UBS said. Estimates also lowered on 2013 guidance. Buy rating.
Endo Health Solutions numbers lowered at Oppenheimer
Shares of ENDP now seen reaching $32, Oppenheimer said. Estimates also lowered generic competition. Outperform rating.
Endo Pharmaceuticals downgraded at Piper
ENDP was downgraded from Overweight to Neutral, Piper Jaffray said. Opana ER is facing generic competition. $28 price target.
Endo Health downgraded at Needham
ENDP was downgraded from Hold to Underperform, Needham said. Core franchises will likely continue to deteriorate.
Endo numbers cut at UBS
Shares of ENDP now seen reaching $45, UBS said. Estimates also lowered following investor day. Buy rating.
Endo Pharmaceuticals added to US 1 List at BofA/Merrill
ENDP was placed on the US 1 list, Bank of America/Merrill Lynch said. Opana ER market share should soon recover. Buy rating and $40 price target.
- 1
- 2
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.